WO2009034431A3 - Formes posologiques à libération contrôlée de la varenicline - Google Patents

Formes posologiques à libération contrôlée de la varenicline Download PDF

Info

Publication number
WO2009034431A3
WO2009034431A3 PCT/IB2008/002311 IB2008002311W WO2009034431A3 WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3 IB 2008002311 W IB2008002311 W IB 2008002311W WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3
Authority
WO
WIPO (PCT)
Prior art keywords
varenicline
controlled
dosage forms
release dosage
antioxidant
Prior art date
Application number
PCT/IB2008/002311
Other languages
English (en)
Other versions
WO2009034431A2 (fr
Inventor
Barbara Alic Johnson
Kenneth Craig Waterman
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2009034431A2 publication Critical patent/WO2009034431A2/fr
Publication of WO2009034431A3 publication Critical patent/WO2009034431A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une composition pharmaceutique à libération contrôlée de la varenicline ou d'un sel pharmaceutiquement acceptable de cette dernière, ladite composition pharmaceutique à libération contrôlée comprenant un enrobage et un antioxydant, l'antioxydant étant présent dans une quantité égale à un pourcentage en poids compris entre environ 0,1% et 55 de la couche d'enrobage.
PCT/IB2008/002311 2007-09-10 2008-08-29 Formes posologiques à libération contrôlée de la varenicline WO2009034431A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97101707P 2007-09-10 2007-09-10
US60/971,017 2007-09-10

Publications (2)

Publication Number Publication Date
WO2009034431A2 WO2009034431A2 (fr) 2009-03-19
WO2009034431A3 true WO2009034431A3 (fr) 2009-11-19

Family

ID=40032575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002311 WO2009034431A2 (fr) 2007-09-10 2008-08-29 Formes posologiques à libération contrôlée de la varenicline

Country Status (1)

Country Link
WO (1) WO2009034431A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400964A4 (fr) * 2016-01-08 2019-08-21 CTC Bio, Inc. Préparation pharmaceutique à usage oral et goût masqué contenant de la varénicline ou un sel pharmaceutiquement acceptable de celle-ci
KR20180058644A (ko) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 바레니클린 서방성 제제 및 이의 제조 방법
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
WO2018154395A2 (fr) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique à libération contrôlée de varénicline
KR102235848B1 (ko) * 2019-11-20 2021-04-05 충북대학교 산학협력단 바레니클린 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
CN117479927A (zh) * 2021-06-25 2024-01-30 汉达医药股份有限公司 稳定的伐尼克兰剂型
EP4169516A1 (fr) * 2021-11-05 2023-04-26 Alfred E. Tiefenbacher (GmbH & Co. KG) Prévention de la conversion d'agents pharmaceutiques en composés n-nitrosamine toxiques
WO2023012376A2 (fr) * 2021-11-05 2023-02-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Prévention de la conversion d'agents pharmaceutiques en composés de n-nitrosamine toxiques
KR20230068877A (ko) * 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN114088843B (zh) * 2021-11-26 2024-01-30 上海皓鸿生物医药科技有限公司 一种伐伦克林中间体中亚硝胺类基因毒性杂质的检测方法
WO2023275413A2 (fr) * 2021-12-23 2023-01-05 Medichem, S.A. Formulations pharmaceutiques solides de varénicline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4093105A (en) 1977-10-19 1978-06-06 N. T. Gates Company Plastic container with vent means
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US6133361A (en) 1996-02-03 2000-10-17 Mitsubishi Gas Chemical Company, Inc. Oxygen-absorbing composition, oxygen-absorbing resin composition, packing material, multi-layered packing, oxygen absorber packet, packing method and preservation method
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US6410550B1 (en) 1997-12-31 2002-06-25 Pfizer Inc Aryl fused azapolycyclic compounds
CA2420535A1 (fr) 2000-08-30 2002-03-07 Mary Tanya Am Ende Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
EP1243524A3 (fr) 2001-03-16 2004-04-07 Pfizer Products Inc. Trousse pharmaceutique pour médicaments sensibles a l'oxygène
AU2002351008B2 (en) 2001-11-30 2007-07-12 Pfizer Products Inc. Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KENNETH C WATERMAN ET AL: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 97, no. 4, 1 April 2008 (2008-04-01), pages 1499 - 1507, XP008111696, ISSN: 0022-3549 *
PUZ MICHAEL J ET AL: "Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug.", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY 2005, vol. 10, no. 1, 2005, pages 115 - 125, XP002546552, ISSN: 1083-7450 *
WATERMAN ET AL.: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", J PHARM SCI, vol. 97, no. 4, 21 August 2007 (2007-08-21), pages 1499 - 1507, XP002546561, Retrieved from the Internet <URL:http://www3.interscience.wiley.com/journal/115805949/abstract?CRETRY=1&SRETRY=0> [retrieved on 20090909] *

Also Published As

Publication number Publication date
WO2009034431A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009034431A3 (fr) Formes posologiques à libération contrôlée de la varenicline
WO2009113703A3 (fr) Préparation solide orodispersible
WO2011084593A3 (fr) Formulations empêchant un usage abusif
WO2011106416A3 (fr) Formulations à l&#39;épreuve d&#39;un usage abusif
WO2009008006A3 (fr) Compositions pharmaceutiques d&#39;administration gastro-intestinale de médicaments
NZ600123A (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
NZ610701A (en) Once daily formulation of lacosamide
WO2011039768A3 (fr) Compositions pharmaceutiques pour réduire une libération massive induite par l&#39;alcool
WO2009092129A8 (fr) Composition pharmaceutique de duloxétine à libération retardée
NZ589469A (en) Niacin and NSAID combination for reducing niacin-induced flushing
WO2007103557A3 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
WO2009059701A3 (fr) Comprimés à libération prolongée contenant de l&#39;hydromorphone
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
NZ589017A (en) Solid pharmaceutical formulation with delayed release
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
JP2013508289A5 (fr)
WO2009057138A3 (fr) Compositions pharmaceutiques à libération régulée de toltérodine
WO2008008592A3 (fr) Formulation multiparticulaire comprenant du tramadol sous forme à libération immédiate et à libération contrôlée
WO2010001413A3 (fr) Compositions pharmaceutiques à libération prolongée comportant la quétiapine
WO2009072334A1 (fr) Particule de cœur pour préparation pharmaceutique
WO2008062475A3 (fr) Compositions pharmaceutiques d&#39;ursodiol
TN2011000307A1 (en) Galenic formulation of organic compounds
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
WO2008056375A3 (fr) Formulations pharmaceutiques comprenant du valsartan
WO2011141791A3 (fr) Formulations à libération prolongée de la base desvenlafaxine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2